Table 3.
Patient use of medications and laboratory test results upon enrollment in the SAKURA AF Registry.
| Total patients | DOAC users | Warfarin users | P value⁎ | |
|---|---|---|---|---|
| (n=3266) | (n=1689) | (n=1577) | ||
| New use | 645 (19.7) | 564 (33.4) | 81 (5.1) | <0.0001 |
| Antiplatelet drugs | 513 (15.7) | 207 (12.3) | 306 (19.4) | <0.0001 |
| Aspirin | 385 (11.8) | 151 (8.9) | 234 (14.8) | <0.0001 |
| Ticlopidine | 8 (0.2) | 0 (0.0) | 8 (0.5) | 0.0034 |
| Clopidogrel | 88 (2.7) | 40 (2.4) | 48 (3.0) | 0.2335 |
| Prasugrel | 19 (0.6) | 7 (0.4) | 12 (0.8) | 0.0001 |
| Cilostazol | 31 (0.9) | 10 (0.6) | 21 (1.3) | 0.0294 |
| Other | 25 (0.8) | 16 (1.0) | 9 (0.6) | 0.2172 |
| NSAID | 56 (1.7) | 34 (2.0) | 22 (1.4) | 0.1740 |
| Rate control drugs | 1979 (60.6) | 958 (56.7) | 1021 (64.7) | <0.0001 |
| Digitalis | 436 (13.4) | 172 (10.2) | 264 (16.7) | <0.0001 |
| Ca channel blocker | 436 (13.4) | 214 (12.7) | 222 (14.1) | 0.2374 |
| Beta blocker | 1450 (44.4) | 719 (42.6) | 731 (46.4) | 0.0296 |
| Rhythm control drugs | 740 (22.7) | 407 (24.2) | 333 (21.1) | 0.0382 |
| Class I | 422 (12.9) | 238 (14.1) | 184 (11.7) | 0.0391 |
| Bepridil | 322 (9.9) | 173 (10.3) | 149 (9.4) | 0.4466 |
| Amiodarone | 30 (0.9) | 11 (0.7) | 19 (1.2) | 0.0975 |
| Laboratory test results | ||||
| CrCl (mL/min) | 68.1±26.7 | 70.5±27.4 | 65.6±25.6 | |
| >80 | 901 (27.6) | 495 (29.3) | 406 (25.7) | <0.0001 |
| >50 to 80 | 1535 (47.0) | 810 (47.8) | 725 (46.0) | |
| >30 to 50 | 640 (19.6) | 320 (18.9) | 320 (20.3) | |
| ≤30 | 152 (4.7) | 43 (2.5) | 109 (6.9) | <0.0001 |
| Not reported | 38 (1.2) | 21 (1.2) | 17 (1.1) | |
| NT-proBNP (pg/mL) | 503 (195–1082) | 474 (153–1111) | 524 (238–1063) | 0.0121 |
| Not reported | 834 (25.5) | 462 (27.3) | 372 (23.6) |
Values are shown as the mean±SD, median and interquartile range, or n (%). AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; NT-proBNP, N-terminal pro brain natriuretic peptide; CrCl, creatinine clearance; new use, warfarin or DOAC starting within 3 months after the registration date; Hb, hemoglobin; HDL, high-density lipoprotein; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; NSAID: non-steroidal anti-inflammatory drug; TC, total cholesterol.
⁎
Per the Student t-test, Mann–Whitney test, or chi-square test, as appropriate.